Evidence digest
What the research on DSIP actually shows
The indexed literature on DSIP includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether DSIP is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for DSIP (4).
- Published research is indexed back to 1975, with roughly 519 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether DSIP is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| DSIP in insomniaEuropean neurology · 1984 | Human — controlled trial | Not recorded | — | This paper summarizes different investigations into effects of delta sleep-inducing peptide (DSIP) injections on insomnia. Two different studies showed improvement of sleep following single injections of 25 nmol/kg b.w. before sleep. Repeated administrations indicated a buildup with normalization of sleep structure after four administrations. Repeated injections in the morning - besides increasing daytime activity - still had a strong positive effect on night sleep, but not s… | PMID 6391925 |
| Effects of DSIP on narcolepsyEuropean neurology · 1984 | Case report | Not recorded | — | Repeated injections of delta sleep-inducing peptide (DSIP) were given to a 35-year-old male narcoleptic. Effects on wakefulness and sleep were evaluated by self-reports, performance tests, multiple sleep latency test and all-night polysomnography. DSIP reduced the frequency of sleep attacks and increased activity, alertness and performance during day-time. The sleep period was compressed by DSIP with enhancement of REM sleep. The results suggest that the effects are due to an… | PMID 6548968 |
| A clinical trial with DSIPEuropean neurology · 1984 | Human — controlled trial | Not recorded | — | In an open study 7 patients with severe insomnia were treated by a series of 10 injections with the delta-sleep-inducing peptide (DSIP). In all but 1 case sleep was normalized for follow-up periods of 3-7 months. The mood and performance during the daytime improved as well. A problem may be a long-standing habit of drug addiction. | PMID 6391926 |
| Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomniaEuropean neurology · 1987 | Human — controlled trial | Not recorded | — | Impaired daytime functions are a significant part of chronic insomnia besides sleep disturbance. Therefore, the effects of intermediate-term delta-sleep-inducing peptide (DSIP) administration on sleep and daytime performance were investigated in 14 middle-aged chronic insomniacs. DSIP was administered under placebo-controlled, double-blind conditions for 7 successive nights. Polysomnograms were obtained for placebo baseline, beginning and end of DSIP treatment, and one placeb… | PMID 3622582 |
Vendors listing DSIP
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Next Gen Peptides | 93.897% | 1 | profile → |
| Amino Club | 90.495% | 0 | profile → |
| Ascend Science | 90.291% | 2 | profile → |
| PeptidePlugs | 89.790% | 2 | profile → |
| Hydro Research Peptides | 88.289% | 1 | profile → |
| Protide Health | 83.994% | 1 | profile → |
| American Peptides | 83.6100% | 1 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| NeuroLabs Research | 79.386% | 1 | profile → |
| ZC Labs | 79.384% | 2 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Licensed Peptides | 7789% | 1 | profile → |
| Evo Labs Research | 75.789% | 1 | profile → |
| Modern Aminos | 74100% | 1 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| True Research Labs | 71.971% | 0 | profile → |
| Vertex Labs | 70.170% | 1 | profile → |
| Improved Peptides | 7089% | 0 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Evolve Peptides | 65.567% | 0 | profile → |
| Mile High Compounds | 65.494% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.